ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04326426|
Recruitment Status : Unknown
Verified April 2020 by Vanda Pharmaceuticals.
Recruitment status was: Enrolling by invitation
First Posted : March 30, 2020
Last Update Posted : April 20, 2020
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||August 1, 2020|
|Estimated Study Completion Date :||August 31, 2020|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Smieszek SP, Przychodzen BP, Polymeropoulos VM, Polymeropoulos CM, Polymeropoulos MH. Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients'. Cytokine. 2021 Dec;148:155662. doi: 10.1016/j.cyto.2021.155662. Epub 2021 Jul 29. Erratum in: Cytokine. 2022 Jan;149:155752.